Know Cancer

or
forgot password

A Phase 2 Study of Oral Enzastaurin HCl in Patients With Relapsed Mantle Cell Lymphoma


Phase 2
18 Years
N/A
Not Enrolling
Both
Mantle-Cell Lymphoma

Thank you

Trial Information

A Phase 2 Study of Oral Enzastaurin HCl in Patients With Relapsed Mantle Cell Lymphoma


Inclusion Criteria:



- Mantle Cell Lymphoma

- Previous treatment for Mantle Cell Lymphoma

- Adequate organ function

Exclusion Criteria:

- Inability to swallow tablets

- Must not have had more than 3 prior treatments for Mantle Cell Lymphoma

- Must not have significant heart problems

Type of Study:

Interventional

Study Design:

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

To estimate the rate of freedom from progression for at least 3 cycles in patients with relapsed mantle cell lymphoma who have received enzastaurin.

Outcome Time Frame:

baseline, after 3 cycles

Safety Issue:

No

Principal Investigator

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST)

Investigator Role:

Study Director

Investigator Affiliation:

Eli Lilly and Company

Authority:

United States: Food and Drug Administration

Study ID:

8360

NCT ID:

NCT00088205

Start Date:

March 2004

Completion Date:

May 2008

Related Keywords:

  • Mantle-Cell Lymphoma
  • Lymphoma
  • Lymphoma, Mantle-Cell

Name

Location